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INTRODUCTION
Fragile X mental retardation protein
(FMRP) is a RNA binding protein,
the absence of which due to silenc-
ing of the FMR1 gene causes fragile X
syndrome, an X-linked neurodevelop-
mental disorder (Bassell and Warren,
2008; Bhakar et al., 2012; Santoro et al.,
2012). FMRP regulates the transport,
stability and translation of its mRNA
targets. Loss of FMRP alters transla-
tional control and receptor-mediated
signaling pathways, leading to aberrant
dendritic spine dynamics, synaptic
Abbreviations: 4E-BP2, eIF4E-binding protein 2;
AD, Alzheimer disease; Aβ, β amyloid; AMPAR,
α-amino-3-hydroxyl-4-isoxazole propionic acid
receptors; APP, amyloid precursor protein; Arc,
activity-regulated cytoskeleton-associated protein;
CYFIP, cytoplasmic FMRP interacting protein;
eIF4E, eukaryotic initiation factor 4E; EphB2, ephrin
type-B receptor 2; ERK, extracellular signal related
kinase; FMRP, fragile X mental retardation protein;
GABA, gamma aminobutyric acid; GSK3β, glyco-
gen synthase kinase-3β; hnRNP C, heterogeneous
nuclear ribonucleoprotein C; MAP1A/2, microtubule
associated protein 1A/2; MEK, mitogen-activated
protein kinase/ERK kinase; mGluR5, metabotropic
glutamate receptor 5; Mnk, mitogen-activated pro-
tein kinase interacting kinase; mTOR, mammalian
target of rapamycin; mTORC1, mammalian target
of rapamycin complex 1; NF1, neurofibromatosis
1; NMDAR, N-methyl-d-aspartate receptors; PAK1,
p21-activated kinase 1; PI3K, phosphatidylinosi-
tol 3-kinase; PIKE, PI3K enhancer; PP2A, protein
phosphatase 2A; PrPC, cellular prion protein; PSD-
95, postsynaptic density 95; PTEN, Phosphatase
and tensin homolog; Raptor, regulatory-associated
protein of mTOR; S6K1, p70 ribosomal kinase 1;
SAPAP, SAP90/PSD-95–associated protein; SHANK,
Src homology 3 (SH3) and multiple ankyrin repeat
domains protein; STEP, striatal-enriched protein
tyrosine phosphatase; SYNGAP1, synaptic Ras guano-
sine triphosphatase (GTPase)–activating protein 1;
TSC1/2, tuberous sclerosis complex 1/2.
dysfunction and behavioral phenotypes in
fragile X syndrome (Wang et al., 2012;
Sidorov et al., 2013; Suhl et al., 2014). Since
the identification of FMR1 as the causative
gene for fragile X syndrome in 1991, stud-
ies have mainly focused on understanding
the function of FMRP. More and more
potential FMRP mRNA targets and inter-
acting proteins have been identified in the
mammalian brain, supporting the criti-
cal roles of FMRP in neurodevelopment,
synaptic plasticity and other neurological
disorders apart from fragile X syndrome
(Wang et al., 2008b, 2012; Pasciuto and
Bagni, 2014a; Suhl et al., 2014).
Fragile X syndrome, the most com-
mon monogenic cause of autism spec-
trum disorders (ASDs), has been leading
the way for better understanding of
autism and other neurodevelopmental dis-
orders (Belmonte and Bourgeron, 2006;
Bhakar et al., 2012; Banerjee et al., 2014;
Cook et al., 2014). Clinically, a substan-
tial proportion of children with frag-
ile X syndrome meets diagnostic criteria
for ASDs (Budimirovic and Kaufmann,
2011). Genetically and biologically, many
of the neuronal targets of FMRP over-
lap with genes associated with ASDs,
suggesting the common pathways that
are dysregulated and might be poten-
tial therapeutic targets for these neurode-
velopmental disorders (Auerbach et al.,
2011; Zoghbi and Bear, 2012; Darnell
and Klann, 2013). Interestingly, studies
in recent years have further revealed that
FMRP regulates a multitude of synaptic
proteins and components of signaling
pathways that not only affect neurode-
velopment, but also contribute to the
pathogenesis of neurodegenerative dis-
eases such as Alzheimer disease (AD), the
leading cause for dementia in the elderly
(Malter et al., 2010; Sokol et al., 2011;
Westmark et al., 2011; Hamilton et al.,
2014). FMRPmay play a pivotal role in the
association between neurodevelopmental
and neurodegenerative disorders across
lifespan.
FMRP AND AD PATHOGENESIS
AD is pathologically characterized by
the presence of plaques comprised of β
amyloid (Aβ) and neurofibrillary tangles
(NFTs) containing hyperphosphorylated
tau protein (Selkoe, 2011; Holtzman et al.,
2012; Ubhi and Masliah, 2013; Bloom,
2014). A considerable amount of evi-
dence suggests that soluble Aβ oligomers
are the predominant neurotoxic species of
Aβ, with Aβ42 fragment as the particu-
larly potent form (Klyubin et al., 2012;
Masters and Selkoe, 2012; Klein, 2013).
Aβ oligomers exert the toxic effects by
binding to their receptors on neuronal
synapses, disrupting normal synaptic sig-
naling pathways, which further leads to
synaptic damage accompanied by neu-
ronal loss (Benilova et al., 2012; Sheng
et al., 2012; Pozueta et al., 2013; Wang
et al., 2013; Tu et al., 2014).
FMRP IN AβMEDIATED SYNAPTIC TOXICITY
A growing number of synaptic proteins
have been proposed as potential Aβ recep-
tors or coreceptors, which are believed
to mediate Aβ induced synaptic dys-
function (Karran et al., 2011; Paula-
Lima et al., 2013; Pozueta et al., 2013;
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 43 | 1
CELLULAR NEUROSCIENCE
Wang FMRP and Alzheimer disease pathogenesis
Overk andMasliah, 2014). Those receptors
include, but are not limited to, NMDARs,
mGluR5, AMPARs, cellular prion pro-
tein (PrPC), PSD-95, and EphB2 (Lacor
et al., 2004; Lauren et al., 2009; Cisse
et al., 2011; Larson and Lesne, 2012;Mucke
and Selkoe, 2012; Um et al., 2013; Tu
et al., 2014). In fact, some of Aβ recep-
tors (NMDARs, mGluR5, and PSD-95)
and their associated scaffolding proteins
and adhesion molecules such as SAPAP,
Shank, Homer, and SynGAP1, are those
whose mRNAs are FMRP targets (Darnell
and Klann, 2013; Santini and Klann,
2014), suggesting that FMRP might be
involved in initiating toxic effects of Aβ
oligomers through regulating Aβ receptors
(Figure 1A).
Aβ induced synaptic dysfunction/loss
is a complicated process involving mul-
tiple signaling pathways and biological
events (Benilova et al., 2012; Tu et al.,
2014). FMRP may be implicated in this
process through selective regulation of
components in those signaling pathways
perturbed by Aβ oligomers (Figure 1A).
Binding of glutamate receptors (NMDARs,
mGluR5, and AMPARs) by Aβ oligomers
impairs glutamatergic neurotransmission
and triggers aberrant activation of down-
stream pathways, including PI3K-Akt-
mTOR and MEK-ERK signaling pathways
(Benilova et al., 2012; Pozueta et al., 2013)
which are coupled to cap-dependent trans-
lation (Darnell and Klann, 2013; Santini
and Klann, 2014). FMRP may regulate the
activity of these translational control path-
ways directly since several components
(PIKE, PI3K, mTOR, S6K1, and ERK)
and negative regulators (PTEN, NF1, and
STEP) of the pathways are FMRP tar-
gets (Figure 1A). FMRP also plays a crit-
ical role in regulating the balance of
cap-dependent translation of its target
mRNAs (Darnell and Klann, 2013; Sidorov
et al., 2013; Santini and Klann, 2014).
Dysregulation of the translational con-
trol pathways caused by Aβ oligomers
will affect the protein products of FMRP
targets, including Aβ precursor protein
(APP), ARC, STEP, PTEN, GSK3β and
other molecules which are closely linked to
AD or other neurodegenerative disorders
(Figure 1A), further associating FMRP
with neurodegeneration.
Aβ induced synaptic degeneration also
involves surface removal and endocytosis
of glutmate receptors (NMDARs and
AMPARs) (Um et al., 2012; Boehm, 2013;
Tu et al., 2014). The FMRP targets, such
as the scaffolding protein PSD-95 and
SAPAP3, immediate-early gene product
Arc, protein kinase CaMKII and tyrosine
phosphatase STEP, are key determinants
of NMDAR or AMPAR endocytosis. PSD-
95 and SAPAP3 tethers the receptors to
signaling proteins and neuronal cytoskele-
ton (Wang et al., 2010; Chen et al.,
2011); Arc is a component of AMPAR
endocytosis machinery and regulates the
endocytosis rate (Chowdhury et al., 2006;
Waung et al., 2008); CaMKII and STEP
mediate surface expression or internaliza-
tion of NMDARs and AMPARs through
phosphorylation/dephosphorylation of
relative receptor subunits (Wang et al.,
2008b; Zhang et al., 2008; Lisman et al.,
2012), supporting possible involvement
of FMRP in glutmate receptor endocyto-
sis (Figure 1A). The actin disorganization
contributes to AD pathogenesis (Maloney
and Bamburg, 2007; Bamburg and Bloom,
2009; Penzes and Vanleeuwen, 2011).
The Rac1/PAK1 signaling downstream
of EphB2 is involved in actin cytokele-
ton remodeling; CYFIP1/2 are linked to
Rac1. Binding of EphB2 by Aβ oligomers
stimulates PAK1, which further induces
cofilin phosphorylation to mediate actin
depolymerization, thereby inducing actin
network disorganization, dendritic spine
shrinkage and loss (Ma et al., 2012;
Abekhoukh and Bardoni, 2014; Cisse
and Checler, 2014). In this signaling
pathway, Rac1 is a FMRP target, and
CYFIP1/2 and PAK interact with FMRP
(Figure 1A). Thus, FMRP is likely to play
a role in actin disorganization in AD
pathogenesis.
The presence of hyperphosphorylated
tau enriched NFTs is a classical AD
pathological hallmark. Tau, a microtubule
associated protein (MAP), becomes hyper-
phosphorylated and disassociated from
microtubules under pathological condi-
tions, subsequently forming soluble aggre-
gates, insoluble filaments, and eventually
NFTs in affected brain regions (Medina
and Avila, 2014; Zempel and Mandelkow,
2014). Studies have shown that Aβ-
induced synaptic loss and toxicity are tau
dependent (Vossel et al., 2010; Roberson
et al., 2011). There is a causal associ-
ation between oligomeric Aβ exposure
and tau phosphorylation (Larson et al.,
2012; Boehm, 2013). Tau phosphoryla-
tion is regulated by a balance between
tau kinase and phosphatase activities.
Disruption of this balance by Aβ expo-
sure is suggested to cause abnormal tau
phosphorylation and thereby contributes
to tau aggregation (Wang et al., 2007;
Martin et al., 2013a,b). Of the tau pro-
tein kinases, GSK3β, CaMKII, ERK1/2,
and S6K1 are known to be FMRP tar-
gets (Figure 1A). The decrease in the lev-
els or activity of protein phosphatase(s)
that dephosphorylate tau also contributes
to AD pathology (Braithwaite et al.,
2012; Martin et al., 2013a); among these
phosphatases, PP2A, STEP, and PTEN
are FMRP targets (Figure 1A). FMRP
thus, might be involved in tau pathology
through regulating those tau kinases and
phosphatases. Hyperphosphorylated tau
sequesters normal tau, and the other two
major MAPs (MAP1 and MAP2), caus-
ing disruption of microtubules and mis-
folding of tau (Zempel and Mandelkow,
2014). Notably, both MAP1A and MAP2
are FMRP targets, further implicating
FMRP in neurofibrillary degeneration
(Figure 1A).
FMRP IN Aβ STIMUIATED APP SYNTHESIS
Aβ is produced by the sequential pro-
teolytic cleavage of APP by β- and
γ-secretases via amyloidogenic pathway
(Masters and Selkoe, 2012). The expres-
sion of APP can be upregulated upon
mGluR5 stimulation. FMRP, which is also
regulated by mGluR5 (Ronesi and Huber,
2008; Wang et al., 2008a; Wang and Zhuo,
2012), binds to and represses the trans-
lation of APP mRNA due to mGluR5
activation (Westmark and Malter, 2007;
Westmark, 2013).
The mGluR5 links FMRP with APP. It
is known that mGluR5 acts as a corecep-
tor for Aβ oligomers bound to PrPC (Um
et al., 2013). Aβ oligomers can stimulate
APP synthesis through the mGluR5 and
protein translation dependent pathway
which involves FMRP, providing template
for secretase cleavage to produce Aβ and
other metabolites (Westmark and Malter,
2007;Westmark, 2013). Aβ oligomer inter-
actions with mGluR5-PrPC may function
to accelerate Aβ production through the
FMRP dependent signaling pathway, sug-
gesting that a positive feedback loop may
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FIGURE 1 | Potential roles of FMRP in the pathogenesis of AD. (A) FMRP
might be involved in oligomeric Aβ induced neurotoxicity. At pathological
concentrations, Aβ oligomers may interact with multiple neuronal synaptic
receptors such as mGluR5-PrPC, NMDARs, AMPARs, and EphB2, triggering a
series of toxic synaptic events which may involve FMRP and eventually lead
(Continued)
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FIGURE 1 | Continued
to synaptic dysfunction and neuronal loss. These events include: Aberrant
activation of PI3K-Akt-mTORC1 and MEK-ERK signaling pathways linked to
cap-dependent translation result in altered synthesis of synaptic proteins;
Oligomeric Aβ exposure disrupts the balance between tau kinase (GSK3β,
CaMKII, Akt, Fyn, and ERK1/2) and phosphatase (PP2A, STEP, and PTEN)
activities, inducing tau hyperphosphorylation and aggregation; Stimulating
EphB2-Rac1/PAK1 signaling by Aβ oligomers induces cofilin
phosphorylation and actin depolymerization, leading to actin network
disorganization; Binding of Aβ oligomers to PrPC-mGluR5 activates Fyn
kinase which phosphorylates not only tau, but also NR2B subunit of
NMDARs, enhancing NMDAR activity and causing excitotoxicity; STEP is
also activated, inactivates Fyn, and dephosphorylates AMPARs and
NMDARs, resulting in endocytosis of glutamate receptors, a cellular
process involves Arc, PSD-95, SAPAP, and other synaptic proteins. Purple
proteins are those whose mRNAs are FMRP targets (Darnell and Klann,
2013; Pasciuto and Bagni, 2014b; Santini and Klann, 2014); the blue ones
are the interacting proteins of FMRP (Pasciuto and Bagni, 2014a). Proteins
with red lines around them indicate those that have been successfully
manipulated either pharmacologically or genetically to reverse molecular,
cellular and/or behavioral phenotypes in animal models of AD (Zhang et al.,
2010; Malinow, 2012; Caccamo et al., 2014; Feld et al., 2014; Hamilton
et al., 2014; Llorens-Martin et al., 2014) as well as ASDs (Goebel-Goody
et al., 2012; Guo et al., 2012; Won et al., 2012; Darnell and Klann, 2013;
Osterweil et al., 2013; Wang and Doering, 2013; Wang, 2014). Proteins
with black lines around them are the ones that have been reported to be
potential targets for AD therapy (Griffin et al., 2005; Lafay-Chebassier
et al., 2005; Ma et al., 2008; Cisse et al., 2011; Moriguchi, 2011; Chang
et al., 2012; Gross and Bassell, 2014; Nygaard et al., 2014; Sontag and
Sontag, 2014). (B) FMRP in APP synthesis. Aβ oligomers stimulate
dendritic APP synthesis through PrPC-mGluR5 mediated protein translation
dependent pathway, providing template for secretase cleavage to produce
Aβ and other metabolites. A positive feedback may exist whereby
production of APP results in increased substrate for amyloidogenic
processing and release of Aβ, which then acitivates mGluR5 to further
stimulate APP translation. In this process, FMRP competes with the other
RNA binding protein hnRNP C to modulate APP translation. FMRP is a
repressor of APP translation, whereas hnRNP C acts as an enhancer. The
rate of APP synthesis is directly influenced by the relative association of
each RNA binding protein (Lee et al., 2010). In signaling pathways, arrows
indicate positive (green) or inhibitory (red) consequence on downstream
components, but they do not necessarily represent direct interactions.
exist in AD, whereby translation of APP
results in increased substrate for amy-
loidogenic processing and generation of
Aβ which then stimulates mGluR5 sig-
naling to induce further synaptic syn-
thesis of APP (Westmark and Malter,
2007; Westmark, 2013) (Figure 1B). Thus,
in addition to the established role in
fragile X syndrome and autism, FMRP
likely contributes directly to AD patho-
genesis through mGluR5 dependent APP
production.
FMRP TARGETS AND AD THERAPY
As discussed above, a number of signaling
pathways, including PI3K-Akt-mTORC1,
MEK-ERK and PAK1 pathways, have been
found to be involved in the neurodegener-
ative progression of AD. Therapies for AD
might require the development of drugs
targeting these aberrant signaling path-
ways, among which several key signaling
proteins such as PI3K, mTOR, ERK and
PAK1, are targets of FMRP. In addition,
the FMRP targeted Aβ oligomer recep-
tors including mGluR5 and NMDARs
could be ideal therapeutic targets for
AD (Figure 1A). Particularly, pharmaco-
logical inhibition or genetic deletion of
mGluR5 was recently found to rescue
learning deficits, or reduce Aβ oligomers
and plaques in AD mice (Um et al., 2013;
Hamilton et al., 2014).
Tau plays crucial roles in the neuronal
cytoskeleton stabilization and is an impor-
tant target for AD therapies (Gotz et al.,
2012; Himmelstein et al., 2012; Giacobini
and Gold, 2013). Interventions focused
on preventing or reducing tau hyperphos-
phorylation and mislocalization may pro-
vide additional strategies for treatment
of AD. The therapeutic tactics include
Tau kinase inhibitors and phosphatase
activators (Giacobini and Gold, 2013;
Zempel and Mandelkow, 2014). The rel-
evant kinases and phosphatases could
be the FMRP targets such as GSK3β,
ERK, S6K1, PP2A, PTEN, and STEP
(Figure 1A). Although the tau based treat-
ments are encouraging, additional work
are undoubtedly needed to optimize each
treatment for further development of safe
and effective therapies.
Therefore, FMRP targeted signaling
molecules not only provide therapeutic
strategies for fragile X syndrome and other
ASDs (Darnell and Klann, 2013; Santini
and Klann, 2014), but may serve as poten-
tial targets for treatment of AD. Indeed,
many components of altered signaling
pathways in AD overlap with those in
ASDs. A number of signaling proteins tar-
geted by FMRP have been successfully
manipulated either pharmacologically or
genetically to reverse molecular, cellular
and/or behavioral phenotypes in animal
models of both ASDs and AD (Figure 1A).
FMRP thus, acts as a molecular link
between ASDs and AD through the com-
mon signaling pathways among the dis-
eases. Developing novel therapies directed




It is now known that FMRP controls
signaling pathways that could be associ-
ated with both neurodevelopmental and
neurodegenerative disorders. FMRP not
only regulates gene expression at the
translational level, but also interacts with
a multitude of proteins at both presy-
naptic and postsynaptic sites (Pasciuto
and Bagni, 2014a; Myrick et al., 2015).
However, so far no systemic proteomic
analysis of FMRP interactome in brain
has been reported. Additionally, although
many of the interacting proteins of FMRP
such as transactive response DNA-binding
protein-43 (TDP-43), survival of motor
neuron 1 (SMN1) and CYFIP are known
to be linked to neurological disorders
(Abekhoukh and Bardoni, 2014; Pasciuto
and Bagni, 2014a), the significance of the
protein-protein interaction to individual
proteins and diseases still need to be fur-
ther characterized.
The AD animal or cell models are pow-
erful tools for investigating the pathogen-
esis of the neurodegenerative disease. It
will be useful to set up the transgenic AD
mice/Aβ-treated primary neuronal culture
which either lack or overexpress FMRP
for further evaluating the pathological role
of FMRP in AD. FMRP regulates specific
mRNA/protein targets at different devel-
opmental stages and in different brain
areas. Future studies will need to provide
detailed information on FMRP mRNA
targets and FMRP interactome in rele-
vant brain areas at specific developmental
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stages of AD animal models. The informa-
tion will greatly help to further elucidate
the pathogenesis of this neurodegenerative
disease and develop relative therapeutic
strategies.
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